Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
activist, agenda, appellate, awaiting, BAL, cardiac, CFO, cheaper, CI, coordinating, criterion, CSF, denote, depository, download, DPF, dynamic, electrocardiogram, ensitrelvir, enstirelvir, eradication, Erroneously, Eurasia, extraordinary, FDIC, fit, formula, fundamental, fundraising, futile, futility, gave, hoc, immaterial, Invivyd, landlord, Likewise, macroeconomic, nasopharyngeal, NextGen, NIST, Nsp, obeldesivir, officially, PCR, Pharmacy, premarket, PTAB, purportedly, Qatar, receptive, reoccurrence, repolarization, resilient, resorting, Retail, runway, Schema, seeded, shareholder, Silicon, speculative, sponsorship, Sr, subscription, sunsetting, surpassed, surveyed, thrive, underway, uninterrupted, Unitary, unrestricted, UPC, uphold, Valley, vast, velpatasivir, VP, weekly, Xocova, yearly
Removed:
absence, AG, Aid, allocating, Alnylam, altogether, analyze, analyzing, anemia, antibody, Asia, assembled, AstraZeneca, attachment, authored, backup, belonging, beneficially, bilayer, bind, Biogen, Biopharma, breath, bundled, call, capsid, catalyze, Chiron, circulate, clarity, Codification, cofounded, cold, collateralize, combat, comprise, conservation, constraint, coronaviridae, cough, dddp, ddrp, deteriorate, directed, dollar, dsRNA, East, elderly, Enanta, encased, envelope, enveloped, Epivir, euro, executed, exemption, exert, expedient, fatigue, feel, forecast, fourth, furnishing, genotype, GlaxoSmithKline, glycoprotein, Golgi, heightening, hemolytic, Hoffmann, hybrid, immigration, indefinite, inferred, intention, judgement, kidney, La, makeup, marketability, measuring, messenger, metabolic, Middle, mimic, minimize, mistakenly, month, movement, muscle, nascent, neutralizing, nonstructural, nucleic, nucleocapsid, obesity, OPM, opportunistically, overcome, overwork, partly, pattern, paused, permeation, pound, practical, precautionary, predominant, prevalent, prioritization, prioritized, promised, proportional, protective, provincial, PWERM, quantitation, redeemable, region, reinvestment, Relenza, representing, reversal, Reyataz, RSV, sequelae, serine, shell, Shield, Shire, soliciting, Southeast, spherical, spread, sterling, strain, structurally, subsided, Summer, surface, Sustiva, syncytial, syndrome, synthetic, TCA, template, teratogenicity, termed, threatening, throat, tract, transcribe, transcribed, transferred, transferring, transitional, translated, transmembrane, transport, turnover, Tyzeka, unapproved, unbilled, Valeant, Valtrex, Videx, virally, virion, Weakening, Wellferon, wholesale, worked, Xofluza, Zerit, Zika
Filing tables
Filing exhibits
Related press release
Associated AVIR transcripts
AVIR similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Atea Pharmaceuticals, Inc. (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2024 |
| By: | /s/ Jean-Pierre Sommadossi | |
| Jean-Pierre Sommadossi, Ph.D. | |||
| President and Chief Executive Officer (principal executive officer) |